Format

Send to

Choose Destination
Biologicals. 2011 Sep;39(5):339-42. doi: 10.1016/j.biologicals.2011.06.009. Epub 2011 Jul 23.

Regulatory guidelines for biosimilars in Malaysia.

Author information

1
Biotechnology Section, National Pharmaceutical Control Bureau, Ministry of Health Malaysia, Jalan University, Petaling Jaya, Selangor, Malaysia. aarpah@bpfk.gov.my

Abstract

The biosimilars sector continues to attract huge interest and controversy. Biosimilars are new biopharmaceuticals that are "similar" but not identical to the innovator product. Characteristics of biopharmaceuticals are closely related to the manufacturing process, which implies that the products cannot be exactly duplicated. Minuscule differences in the product's structure and manufacturing process can result in different clinical outcome. This raises concerns over the safety, efficacy and even pharmacovigilance of biosimilars. Thus, biosimilars are unique - they are not a true chemical generic and are regulated via a distinct regulatory framework. This report discusses the features of Malaysian regulatory oversight of biosimilars and experience acquired in the evaluation of some products from various countries. Ensuring regulatory position adequately reflects scientific advancement, expertise/resources is key. The regulatory situation is an evolving process. Various guidance documents are being prepared with the aim of developing a uniform global framework towards assuring the dual goal of lower costs and patient safety while expediting the availability of important biosimilar products.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center